<DOC>
	<DOC>NCT00267930</DOC>
	<brief_summary>This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration</brief_summary>
	<brief_title>Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>Inclusion Criteria (partial list): Subjects must have sustained, symptomatic atrial fibrillation for greater than 72 hours and less than 6 months duration Subjects must have adequate anticoagulant therapy Exclusion Criteria (partial list): Subjects may not have Class III or Class IV congestive heart failure Subjects may not have uncorrected electrolyte imbalance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>AFib</keyword>
	<keyword>AF</keyword>
</DOC>